Woodline Partners LP Nanobiotix S.A. Transaction History

Woodline Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.53 - $7.44 $15,104 - $31,835	-4,279 Reduced 24.75%	13,009 $49,000
Q1 2022 May 16, 2022	SELL	$6.11 - $9.85 $154,485 - $249,047	-25,284 Reduced 59.39%	17,288 $121,000
Q4 2021 Feb 14, 2022	SELL	$7.13 - $13.04 $64,619 - $118,181	-9,063 Reduced 17.55%	42,572 $345,000
Q3 2021 Nov 15, 2021	SELL	$11.36 - $15.0 $94,958 - $125,385	-8,359 Reduced 13.93%	51,635 $587,000
Q2 2021 Aug 16, 2021	SELL	$13.78 - $17.79 $62,285 - $80,410	-4,520 Reduced 7.01%	59,994 $827,000
Q1 2021 May 17, 2021	SELL	$14.95 - $19.68 $82,015 - $107,964	-5,486 Reduced 7.84%	64,514 $970,000
Q4 2020 Feb 16, 2021	BUY	$15.95 - $19.4 $1.12 Million - $1.36 Million	70,000 New	70,000 $1.16 Million

9.29M

Ticker NBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,875,900
Market Cap $201M
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.